Late Lumen Loss Measurement

Known as: LATELOSS, Late Loss 
The difference between the mean minimum lumen diameter (MLD) assessed immediately after an index procedure and the MLD assessed at follow-up… (More)
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study.
OBJECTIVES The aim of this study was to evaluate the efficacy of drug-eluting balloons (DEB) compared with paclitaxel-eluting… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
BACKGROUND A fully bioabsorbable drug-eluting coronary stent that scaffolds the vessel wall when needed and then disappears once… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results…
BACKGROUND The use of the Endeavor stent might reduce restenosis and stent thrombosis at 9 months. METHODS AND RESULTS Patients… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison.
BACKGROUND Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. Early evaluations of new… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial.
OBJECTIVES We sought to evaluate the relationship between angiographic late loss and clinical outcomes in the drug-eluting stent… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.
PURPOSE To investigate further the safety and efficacy of the sirolimus-eluting S. M.A.R.T. Nitinol Self-expanding Stent by… (More)
Is this relevant?
Review
2005
Review
2005
Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials.
BACKGROUND Binary angiographic and clinical restenosis rates can vary widely between clinical studies, even for the same stent… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.
BACKGROUND Despite limiting elastic recoil and late vascular remodeling after angioplasty, coronary stents remain vulnerable to… (More)
  • figure 2
  • table 1
  • figure 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
BACKGROUND Stenting likely decreases the need for target-vessel revascularization procedures in diabetic patients compared with… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus.
Diabetes mellitus is a well-known risk factor for the development of atherosclerotic coronary artery disease [1, 2]. Findings in… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?